Focus on Induction Regimens for Transplant-eligible Patients with Multiple Myeloma

Focus on Induction Regimens for Transplant-eligible Patients with Multiple Myeloma
Focus on Induction Regimens for Transplant-eligible Patients with Multiple Myeloma
CME, CPE
Sergio A. Giralt, MD, FACP
Release Date: May 23, 2018
Expiration Date: May 23, 2019

Despite exciting new developments in the number and kind of pharmacologic options available for multiple myeloma (MM), stem cell transplantation remains an important first-line treatment that is often underutilized. This activity will address critical factors that must be considered when making treatment decisions concerning transplant in MM patients, including safety, efficacy, and potential for long-term remission.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No Credit